The effects of EXOPULSE Mollii Suit in patients with fibromyalgia: a double-blind randomized sham-controlled trial (EXOFIB2)
EXOPULSE Mollii Suit led to clinically meaningful improvements in fibromyalgia impact and related outcomes. The results of this work are in line with those of previous trials and support its potential as a home-based neuromodulation therapy for fibromyalgia. Future large-scale studies would help further understand the effects of this medical device.
Authors
- Moussa A. Chalah (ORCID: https://orcid.org/0000-0002-0880-8608)
- Sehriban Diab
- Naji Riachi (ORCID: https://orcid.org/0000-0002-8652-9698)
- Ahmed Shatila (ORCID: https://orcid.org/0009-0003-6640-899X)
- Jean-Pascal Lefaucheur
- Hasan Jaber
- Samar S Ayache
- Mais Jawhari
- Joseph G Mattar
Institutions
- Université Paris-Est Créteil (FR)
- Sheikh Shakhbout Medical City (AE)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centre Hospitalier Sainte-Anne (FR)
- Institut de Psychiatrie et Neurosciences de Paris (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- FHU Neurovasc (FR)
- Lebanese American University (LB)
Publication Details
- Journal
- Pain Medicine
- Published
- 2026-01-21
- DOI
- https://doi.org/10.1093/pm/pnag010
- Primary Topic
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00